Skip to content
SynsoryBio logo

SynsoryBio

SynsoryBio is a YC Winter 2024 (W24) company. Based in Cambridge, MA, USA. Team of 2.

  • Synthetic Biology
  • Biotech
  • Therapeutics
  • Oncology

About SynsoryBio

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

SynsoryBio engineers protein therapeutics that detect their location inside the body and switch on only at diseased tissue, leaving healthy tissue unaffected. The platform encodes conditional activation logic directly into the drug molecule, replacing conventional protein drugs that act systemically and cause off-target toxicity. Target applications include cancer and autoimmune disorders, where that precision widens the usable dose range of highly potent agents.

From the Y Combinator listing

How SynsoryBio describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

"If-then" conditional logic for protein drugs

SynsoryBio is creating next generation, protein therapeutics that sense where they are in the body and only activate at diseased tissue. This technology platform has the potential to expand the therapeutic window of highly potent drugs and apply to many diseases such as cancer and autoimmune disorders.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Location
Cambridge, MA, USA
Team size
2
Status
Active
Stage
Early

Founders (2)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works